羟氯喹在狼疮或类风湿关节炎妊娠中与重大先天畸形风险:一项基于人群的队列研究
该基于人群的队列研究利用瑞典全国登记数据,纳入2006-2021年期间患有系统性红斑狼疮(SLE)或类风湿关节炎(RA)的个体所生的所有单胎,评估妊娠早期暴露于羟氯喹(HCQ)与婴儿重大先天畸形(MCM)风险的关系。结果显示,SLE队列调整后RR为1.29(95%CI 0.65, 2.56),RA队列为1.32(95%CI 0.56, 3.13),合并分析为1.30(95%CI 0.76, 2.23),均未达统计学显著;作者认为妊娠早期暴露于HCQ与MCM风险显著增加无关,在妊娠期管理SLE或RA时HCQ的获益可能大于风险。
要点
- SLE队列中,暴露组MCM风险3.7%,未暴露组3.4%,调整后RR为1.29(95%CI 0.65, 2.56)。
- RA队列中,暴露组MCM风险5.6%,未暴露组4.3%,调整后RR为1.32(95%CI 0.56, 3.13)。
- 合并分析调整后RR为1.30(95%CI 0.76, 2.23),未达统计学显著。
核心结论
- 妊娠早期暴露于HCQ与MCM风险显著增加无关,在妊娠期管理SLE或RA时HCQ的获益可能大于风险。
研究设计与样本
- 基于人群的队列研究,利用瑞典全国登记数据,纳入2006-2021年期间患有SLE或RA的个体所生的所有单胎。
- 暴露定义为妊娠早期填写至少1次HCQ处方,结局为出生后1年内婴儿MCM。
- SLE队列纳入1007例出生(453例暴露),RA队列纳入2500例出生(144例暴露)。
- 采用逆概率治疗加权调整潜在混杂因素(如母亲吸烟、体重指数、孕前糖尿病和皮质类固醇),使用改良Poisson回归模型估计风险比(RR)和95%CI。
主要发现
- SLE队列总体MCM风险为3.6%,暴露组3.7%,未暴露组3.4%。
- RA队列总体MCM风险为4.4%,暴露组5.6%,未暴露组4.3%。
- 调整后RR(95%CI)在SLE队列为1.29(0.65, 2.56),RA队列为1.32(0.56, 3.13),合并分析为1.30(0.76, 2.23)。
- 调整后风险差(暴露 vs 未暴露)较小,SLE为0.9%,RA为1.3%。
- 敏感性分析采用不同暴露和结局窗口,结果相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the infant risk of major congenital malformations (MCM) associated with first-trimester exposure to hydroxychloroquine (HCQ) among mothers with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). METHODS: This population-based cohort study utilized Swedish nationwide registers and included all singleton births (2006-2021) among individuals with prevalent SLE or RA in Sweden. The exposure was filling ≥1 HCQ prescription during the first trimester. The outcome was infant MCM within 1 year of birth. Inverse probability of treatment weighting was applied to adjust for potential confounders (e.g. maternal smoking, body mass index, pregestational diabetes and corticosteroids). Modified Poisson regression models with robust variance were used to estimate risk ratios (RR) and 95% CI. RESULTS: We included 1007 births (453 exposed) and 2500 births (144 exposed) in the SLE and RA cohorts, respectively. The MCM risks in the SLE overall cohort, exposed and unexposed groups were 3.6%, 3.7% and 3.4%, respectively. The corresponding figures in the RA cohort were 4.4%, 5.6% and 4.3%, respectively. The adjusted RRs (95% CI) were 1.29 (0.65, 2.56) in the SLE cohort, 1.32 (0.56, 3.13) in the RA cohort and 1.30 (0.76, 2.23) in the pooled analysis. The adjusted risk difference (exposed vs unexposed) was small (0.9% in SLE and 1.3% in RA). Sensitivity analyses examining different exposure and outcome windows yielded similar findings. CONCLUSION: First-trimester exposure to HCQ was not associated with a significantly increased risk of MCM. HCQ's benefits may outweigh the risks in managing SLE or RA during pregnancy.
引用
- Nguyen NV, Svenungsson E, Dominicus A, et al. Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study. Rheumatology (Oxford). 2025. PMID: 38479815. doi:10.1093/rheumatology/keae168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。